Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 9, 2016, Pages 1481-1507

  Rempe, Ralf G ^a   Hartz, Anika M S ^b   Bauer, Björn ^a  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's; Blood brain barrier; epilepsy; inflammation; intracranial aneurysm; multiple sclerosis; neurodegeneration; Parkinson's disease; stroke

Indexed keywords

BRAIN ENZYME; GELATINASE A; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA;

ALZHEIMER DISEASE; ANIMAL MODEL; BLOOD BRAIN BARRIER; BRAIN ARTERY ANEURYSM; BRAIN CANCER; BRAIN DISEASE; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; EPILEPSY; EPILEPTOGENESIS; HUMAN; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SURVIVAL RATE; ENZYMOLOGY; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY;

BLOOD-BRAIN BARRIER; BRAIN DISEASES; HUMANS; MALE; MATRIX METALLOPROTEINASES; MOLECULAR TARGETED THERAPY;

EID: 84985020873     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X16655551     Document Type: Review

References (322)

1. Stocker W, Grams F, Baumann U, et al. The metzincins -topological, and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci 1995; 4: 823-840
2. Page-McCaw A, Ewald AJ, and Werb Z. Matrix metalloproteinases, and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8: 221-233
3. Gross J, and Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 1962; 48: 1014-1022
4. Eisen AZ, Jeffrey JJ, and Gross J. Human skin collagenase. Isolation, and mechanism of attack on the collagen molecule. Biochim Biophys Acta 1968; 151: 637-645
5. Harper E, Bloch KJ, and Gross J. The zymogen of tadpole collagenase. Biochemistry 1971; 10: 3035-3041
6. Bauer EA, Stricklin GP, Jeffrey JJ, et al. Collagenase production by human skin fibroblasts. Biochem Biophys Res Commun 1975; 64: 232-240
7. Woessner JF. Matrix metalloproteinases, and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-2154
8. Van Wart HE, and Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990; 87: 5578-5582
9. Benoit De Coignac A, Elson G, Delneste Y, et al. Cloning of MMP-26. Eur J Biochem 2000; 267: 3323-3329
10. Llano E, Pendas AM, Knauper V, et al. Identification, and structural, and functional characterization of human enamelysin (MMP-20). Biochemistry 1997; 36: 15101-15108
11. Lohi J, Wilson CL, Roby JD, et al. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis, and keratinocytes, and in response to injury. J Biol Chem 2001; 276: 10134-10144
12. Nagase H, Visse R, and Murphy G. Structure, and function of matrix metalloproteinases, and TIMPs. Cardiovasc Res 2006; 69: 562-573
13. Paiva KB, and Granjeiro JM. Bone tissue remodeling, and development: focus on matrix metalloproteinase functions. Arch Biochem Biophys 2014; 561: 74-87
14. Sternlicht MD, and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516
15. Sabeh F, Ota I, Holmbeck K, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 2004; 167: 769-781
16. Song J, Wu C, Zhang X, et al. In vivo processing of CXCL5 (LIX) by matrix metalloproteinase (MMP)-2, and MMP-9 promotes early neutrophil recruitment in IL-1beta-induced peritonitis. J Immunol 2013; 190: 401-410
17. Lee SR, Kim HY, Rogowska J, et al. Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci 2006; 26: 3491-3495
18. Rodríguez D, Morrison CJ, and Overall CM. Matrix metalloproteinases: what do they not do? New substrates, and biological roles identified by murine models, and proteomics. Biochim Biophys Acta 2010; 1803: 39-54
19. Ota I, Li X-Y, Hu Y, et al. Induction of a MT1-MMP, and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proc Natl Acad Sci USA 2009; 106: 20318-20323
20. Cauwe B, Van den Steen PE, and Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 2007; 42: 113-185
21. Morrison CJ, Butler GS, Rodriguez D, et al. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol 2009; 21: 645-653
22. Van Lint P, and Libert C. Chemokine, and cytokine processing by matrix metalloproteinases, and its effect on leukocyte migration, and inflammation. J Leukoc Biol 2007; 82: 1375-1381
23. Manicone AM, Harju-Baker S, Johnston LK, et al. Epilysin (matrix metalloproteinase-28) contributes to airway epithelial cell survival. Respirat Res 2011; 12: 144
24. Yong VW, Power C, Forsyth P, et al. Metalloproteinases in biology, and pathology of the nervous system. Nat Rev Neurosci 2001; 2: 502-511
25. Schubert-Unkmeir A, Konrad C, Slanina H, et al. Neisseria meningitidis induces brain microvascular endothelial cell detachment from the matrix, and cleavage of occludin: a role for MMP-8. PLoS Pathog 2010; 6: e1000874
26. Hartmann C, El-Gindi J, Lohmann C, et al. TIMP-3: a novel target for glucocorticoid signaling at the blood-brain barrier. Biochem Biophys Res Commun 2009; 390: 182-186
27. Deem TL, and Cook-Mills JM. Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species. Blood 2004; 104: 2385-2393
28. Park AJ, Matrisian LM, Kells AF, et al. Mutational analysis of the transin (rat stromelysin) autoinhibitor region demonstrates a role for residues surrounding the cysteine switch. J Biol Chem 1991; 266: 1584-1590
29. Rajagopalan S, Meng XP, Ramasamy S, et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-2579
30. Moon S-K, Cha B-Y, and Kim C-H. ERK1/2 mediates TNF-a-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kB, and AP-1: involvement of the ras dependent pathway. J Cell Physiol 2004; 198: 417-427
31. Cheng G, Wei L, Xiurong W, et al. IL-17 Stimulates migration of carotid artery vascular smooth muscle cells in an MMP-9 dependent manner via p38 MAPK, and ERK1/2-dependent NF-kB, and AP-1 activation. Cell Mol Neurobiol 2009; 29: 1161-1168
32. Wang Y, Wu H, Wu X, et al. Interleukin 17A promotes gastric cancer invasiveness via NF-?B mediated matrix metalloproteinases 2, and 9 expression. PloS ONE 2014; 9: e96678
33. Balasubramanian S, Fan M, Messmer-Blust AF, et al. The interferon-g-induced GTPase, mGBP-2, inhibits tumor necrosis factor a (TNF-a) induction of matrix metalloproteinase-9 (MMP-9) by inhibiting NF-kB, and Rac protein. J Biol Chem 2011; 286: 20054-20064
34. Woo C-H, Lim J-H, and Kim J-H. Lipopolysaccharide induces matrix metalloproteinase-9 expression via a mitochondrial reactive oxygen species-p38 kinase-activator protein-1 pathway in raw 264.7 cells. J Immunol 2004; 173: 6973-6980
35. Green JA, Dholakia S, Janczar K, et al. Mycobacterium tuberculosis-infected human monocytes down-regulate microglial MMP-2 secretion in CNS tuberculosis via TNFalpha, NFkappaB, p38, and caspase 8 dependent pathways. J Neuroinflamm 2011; 8: 46
36. Chakraborti S, Mandal M, Das S, et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253: 269-285
37. Yan C, and Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007; 211: 19-26
38. Peters DG, Kassam A, St Jean PL, et al. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999; 30: 2612-2616
39. Rosenberg GA. Matrix metalloproteinases, and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009; 8: 205-216
40. Abbott NJ, Ronnback L, and Hansson E. Astrocyteendothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53
41. Martin TA, Mansel RE, and Jiang WG. Antagonistic effect of NK4 on HGF/SF induced changes in the transendothelial resistance (TER), and paracellular permeability of human vascular endothelial cells. J Cell Physiol 2002; 192: 268-275
42. Romero IA, Radewicz K, Jubin E, et al. Changes in cytoskeletal, and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. Neurosci Lett 2003; 344: 112-116
43. Zlokovic BV. The blood-brain barrier in health, and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201
44. Cambier S, Gline S, Mu D, et al. Integrin alpha(v)beta8-mediated activation of transforming growth factor-beta by perivascular astrocytes. Am J Pathol 166: 1883-1894
45. Liebner S, Czupalla CJ, and Wolburg H. Current concepts of blood-brain barrier development. Int J Dev Biol 2011; 55: 467-476
46. Verslegers M, Van Hove I, Dekeyster E, et al. MMP-2 mediates Purkinje cell morphogenesis, and spine development in the mouse cerebellum. Brain Struct Funct 2015; 220: 1601-1617
47. Larsen PH, DaSilva AG, Conant K, et al. Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9, and -12 null mice. J Neurosci 2006; 26: 2207-2214
48. Amalinei C, Caruntu ID, Giusca SE, et al. Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol 2010; 51: 215-228
49. Candelario-Jalil E, Yang Y, and Rosenberg GA. Diverse roles of matrix metalloproteinases, and tissue inhibitors of metalloproteinases in neuroinflammation, and cerebral ischemia. Neuroscience 2009; 158: 983-994
50. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002; 39: 279-291
51. Rosenberg GA. Matrix metalloproteinases, and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009; 8: 205-216
52. Yang Y, and Rosenberg GA. Matrix metalloproteinases as therapeutic targets for stroke. Brain Res 2015; 1623: 30-38
53. Zhang S, Kojic L, Tsang M, et al. Distinct roles for metalloproteinases during traumatic brain injury. Neurochem Int 2016; 96: 46-55
54. Lee R, Kermani P, Teng KK, et al. Regulation of cell survival by secreted proneurotrophins. Science 2001; 294: 1945-1948
55. Gurney KJ, Estrada EY, and Rosenberg GA. Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis 2006; 23: 87-96
56. Rosenberg GA, Estrada EY, Dencoff JE, et al. Tumor necrosis factor-a-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 1995; 703: 151-155
57. Rosenberg GA, Kornfeld M, Estrada E, et al. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992; 576: 203-207
58. Rundhaug JE. Matrix metalloproteinases, and angiogenesis. J Cell Mol Med 2005; 9: 267-285
59. Ethell DW, Kinloch R, and Green DR. Metalloproteinase shedding of Fas ligand regulates beta-amyloid neurotoxicity. Curr Biol 2002; 12: 1595-1600
60. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003; 200: 448-464
61. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factoralpha from cells. Nature 1997; 385: 729-733
62. English WR, Puente XS, Freije JM, et al. Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2. J Biol Chem 2000; 275: 14046-14055
63. Kim YS, Choi DH, Block ML, et al. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J 2007; 21: 179-187
64. Kim YS, Kim SS, Cho JJ, et al. Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J Neurosci 2005; 25: 3701-3711
65. Woo MS, Park JS, Choi IY, et al. Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines, and iNOS in microglia. J Neurochem 2008; 106: 770-780
66. Barkho BZ, Munoz AE, Li X, et al. Endogenous matrix metalloproteinase (MMP)-3, and MMP-9 promote the differentiation, and migration of adult neural progenitor cells in response to chemokines. Stem Cells 2008; 26: 3139-3149
67. Sîrbulescu RF, Ilieş I, and Zupanc GKH. Matrix metalloproteinase-2, and -9 in the cerebellum of teleost fish: functional implications for adult neurogenesis. Mol Cell Neurosci 2015; 68: 9-23
68. Chen Q, Moulder K, Tenkova T, et al. Excitotoxic cell death dependent on inhibitory receptor activation. Exp Neurol 1999; 160: 215-225
69. Chen ZL, and Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997; 91: 917-925
70. Duszyk M, Shu Y, Sawicki G, et al. Inhibition of matrix metalloproteinase MMP-2 activates chloride current in human airway epithelial cells. Can J Physiol Pharmacol 1999; 77: 529-535
71. Giancotti FG, and Ruoslahti E. Integrin signaling. Science. 1999; 285: 1028-1032
72. Powell WC, Fingleton B, Wilson CL, et al. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand, and potentiates epithelial cell apoptosis. Curr Biol 1999; 9: 1441-1447
73. Hoehna Y, Uckermann O, Luksch H, et al. Matrix metalloproteinase 9 regulates cell death following pilocarpineinduced seizures in the developing brain. Neurobiol Dis 2012; 48: 339-347
74. Johnston JB, Zhang K, Silva C, et al. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 2001; 49: 230-241
75. Jourquin J, Tremblay E, Decanis N, et al. Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur J Neurosci 2003; 18: 1507-1517
76. Kim GW, Kim HJ, Cho KJ, et al. The role of MMP-9 in integrin-mediated hippocampal cell death after pilocarpine-induced status epilepticus. Neurobiol Dis 2009; 36: 169-180
77. Vos CM, Sjulson L, Nath A, et al. Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord, and dissociated neuronal cultures. Exp Neurol 2000; 163: 324-330
78. Shi Y-B, Fu L, Hasebe T, et al. Regulation of extracellular matrix remodeling, and cell fate determination by matrix metalloproteinase stromelysin-3 during thyroid hormone-dependent post-embryonic development. Pharmacol Therap 2007; 116: 391-400
79. Chandler S, Miller KM, Clements JM, et al. Matrix metalloproteinases, tumor necrosis factor, and multiple sclerosis: an overview. J Neuroimmunol 1997; 72: 155-161
80. Cossins JA, Clements JM, Ford J, et al. Enhanced expression of MMP-7, and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol 1997; 94: 590-598
81. Matyszak MK, and Perry VH. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases. J Neuroimmunol 1996; 69: 141-149
82. Opdenakker G, and Van Damme J. Cytokine-regulated proteases in autoimmune diseases. Immunol Today 1994; 15: 103-107
83. Wang L, Zhang ZG, Zhang RL, et al. Matrix metalloproteinase 2 (MMP2), and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J Neurosci 2006; 26: 5996-6003
84. Folgueras AR, Pendas AM, Sanchez LM, et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004; 48: 411-424
85. Handsley MM, and Edwards DR. Metalloproteinases, and their inhibitors in tumor angiogenesis. Int J Cancer 2005; 115: 849-860
86. Chantrain CF, Henriet P, Jodele S, et al. Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur J Cancer 2006; 42: 310-318
87. Pozzi A, LeVine WF, and Gardner HA. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002; 21: 272-281
88. Andries L, Van Hove I, Moons L, et al. Matrix metalloproteinases during axonal regeneration, a multifactorial role from start to finish. Mol Neurobiol. Epub ahead of print 29 February 2016. DOI: 10.1007/s12035-016-9801-x
89. Hayashita-Kinoh H, Kinoh H, Okada A, et al. Membrane-type 5 matrix metalloproteinase is expressed in differentiated neurons, and regulates axonal growth. Cell Growth Differ 2001; 12: 573-580
90. Tonge D, Zhu N, Lynham S, et al. Axonal growth towards Xenopus skin in vitro is mediated by matrix metalloproteinase activity. Eur J Neurosci 2013; 37: 519-531
91. Vaillant C, Meissirel C, Mutin M, et al. MMP-9 deficiency affects axonal outgrowth, migration, and apoptosis in the developing cerebellum. Mol Cell Neurosci 2003; 24: 395-408
92. Deryugina EI, and Quigley JP. Matrix metalloproteinases, and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34
93. Fingleton B. Matrix metalloproteinases: roles in cancer, and metastasis. Front Biosci 2006; 11: 479-491
94. Larsen PH, Wells JE, Stallcup WB, et al. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 2003; 23: 11127-11135
95. Ito A, Mukaiyama A, Itoh Y, et al. Degradation of interleukin 1b by matrix metalloproteinases. J Biol Chem 1996; 271: 14657-14660
96. McQuibban GA, Gong J-H, Tam EM, et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000; 289: 1202-1206
97. Baeten KM, and Akassoglou K. Extracellular matrix, and matrix receptors in blood-brain barrier formation, and stroke. Dev Neurobiol 2011; 71: 1018-1039
98. Rascher G, Fischmann A, Kroger S, et al. Extracellular matrix, and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin, and agrin. Acta Neuropathol 2002; 104: 85-91
99. Feng S, Cen J, Huang Y, et al. Matrix metalloproteinase-2, and -9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins. PloS ONE 2011; 6: e20599
100. Lischper M, Beuck S, Thanabalasundaram G, et al. Metalloproteinase mediated occludin cleavage in the cerebral microcapillary endothelium under pathological conditions. Brain Res 2010; 1326: 114-127
101. Gu Y, Zheng G, Xu M, et al. Caveolin-1 regulates nitric oxide-mediated matrix metalloproteinases activity, and blood-brain barrier permeability in focal cerebral ischemia, and reperfusion injury. J Neurochem 2012; 120: 147-156
102. Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007; 27: 697-709
103. Gorter JA, Van Vliet EA, Rauwerda H, et al. Dynamic changes of proteases, and protease inhibitors revealed by microarray analysis in CA3, and entorhinal cortex during epileptogenesis in the rat. Epilepsia 2007; 48(Suppl. 5): 53-64
104. Nishikawa M, Yamaguchi Y, Yoshitake K, et al. Effects of TNFa, and prostaglandin E2 on the expression of MMPs in human periodontal ligament fibroblasts. J Period Res 2002; 37: 167-176
105. Hawkes SP, Li H, and Taniguchi GT. Zymography, and reverse zymography for detecting MMPs, and TIMPs. Methods Mol Biol 2010; 622: 257-269
106. Leber TM, and Balkwill FR. Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Analytic Biochem 1997; 249: 24-28
107. Kleiner DE, and Stetlerstevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Analytic Biochem 1994; 218: 325-329
108. Chin JR, Murphy G, and Werb Z. Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. Biosynthesis, isolation, characterization, and substrates. J Biol Chem 1985; 260: 12367-12376
109. Hao L, Du M, Lopez-Campistrous A, et al. Agonistinduced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 2004; 94: 68-76
110. Yu Q, and Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta, and promotes tumor invasion, and angiogenesis. Genes Dev 2000; 14: 163-176
111. Yu W-H, Woessner JF, McNeish JD, et al. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor, and ErbB4, and regulates female reproductive organ remodeling. Genes Dev 2002; 16: 307-323
112. Li C-J, Liu Y, Chen Y, et al. Novel proteolytic microvesicles released from human macrophages after exposure to tobacco smoke. Am J Pathol 2013; 182: 1552-1562
113. Yan SJ, and Blomme EAG. In situ zymography: a molecular pathology technique to localize endogenous protease activity in tissue sections. Veterinary Pathol Online 2003; 40: 227-236
114. Keow JY, Herrmann KM, and Crawford BD. Differential in vivo zymography: a method for observing matrix metalloproteinase activity in the zebrafish embryo. Matrix Biol 2011; 30: 169-177
115. Bell RD, Winkler EA, Singh I, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012; 485: 512-516
116. WHO. Atlas: Multiple sclerosis resources in the world 2008. Geneva: WHO, 2008
117. Compston A, and Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517
118. Agrawal S, Anderson P, Durbeej M, et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 2006; 203: 1007-1019
119. Buhler LA, Samara R, Guzman E, et al. Matrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis. BMC Neurosci 2009; 10: 17
120. Galboiz Y, Shapiro S, Lahat N, et al. Matrix metalloproteinases, and their tissue inhibitors as markers of disease subtype, and response to interferon-beta therapy in relapsing, and secondary-progressive multiple sclerosis patients. Ann Neurol 2001; 50: 443-451
121. Lee MA, Palace J, Stabler G, et al. Serum gelatinase B, TIMP-1, and TIMP-2 levels in multiple sclerosis. A longitudinal clinical, and MRI study. Brain 1999; 122(Pt 2): 191-197
122. Leppert D, Leib SL, Grygar C, et al. Matrix metalloproteinase (MMP)-8, and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage, and neurological sequelae. Clin Infect Dis 2000; 31: 80-84
123. Guo L, Li Y, Lin H, et al. Evaluation of a rat model of experimental autoimmune encephalomyelitis with human MBP as antigen. Cell Mol Immunol 2004; 1: 387-391
124. Kieseier BC, Kiefer R, Clements JM, et al. Matrix metalloproteinase-9, and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998; 121(Pt 1): 159-166
125. Nygardas PT, and Hinkkanen AE. Up-regulation of MMP-8, and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis. Clin Exp Immunol 2002; 128: 245-254
126. Pagenstecher A, Stalder AK, Kincaid CL, et al. Differential expression of matrix metalloproteinase, and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal, and inflammatory states. Am J Pathol 1998; 152: 729-741
127. Weaver A, Goncalves da Silva A, Nuttall RK, et al. An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. FASEB J 2005; 19: 1668-1670
128. Werner SR, Dotzlaf JE, and Smith RC. MMP-28 as a regulator of myelination. BMC Neurosci 2008; 9: 83
129. Toft-Hansen H, Babcock AA, Millward JM, et al. Downregulation of membrane type-matrix metalloproteinases in the inflamed or injured central nervous system. J Neuroinflammation 2007; 4: 24
130. Dubois B, Masure S, Hurtenbach U, et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis, and necrotizing tail lesions. J Clin Invest 1999; 104: 1507-1515
131. Esparza J, Kruse M, Lee J, et al. MMP-2 null mice exhibit an early onset, and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression, and activity. FASEB J 2004; 18: 1682-1691
132. Anthony DC, Ferguson B, Matyzak MK, et al. Differential matrix metalloproteinase expression in cases of multiple sclerosis, and stroke. Neuropathol Appl Neurobiol 1997; 23: 406-415
133. Bar-Or A, Nuttall RK, Duddy M, et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003; 126: 2738-2749
134. Kanesaka T, Mori M, Hattori T, et al. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 185-188
135. Kouwenhoven M, Ozenci V, Gomes A, et al. Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes. J Autoimmun 2001; 16: 463-470
136. Lindberg RL, De Groot CJ, Montagne L, et al. The expression profile of matrix metalloproteinases (MMPs), and their inhibitors (TIMPs) in lesions, and normal appearing white matter of multiple sclerosis. Brain 2001; 124: 1743-1753
137. Lu H, Zeng C, Zhao H, et al. Glatiramer acetate inhibits degradation of collagen II by suppressing the activity of interferon regulatory factor-1. Biochem Biophys Res Commun 2014; 448: 323-328
138. Vos CM, van Haastert ES, De Groot CJ, et al. Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions. J Neuroimmunol 2003; 138: 106-114
139. Leppert D, Ford J, Stabler G, et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses, and stable phases of multiple sclerosis. Brain 1998; 121(Pt 12): 2327-2334
140. Lichtinghagen R, Seifert T, Kracke A, et al. Expression of matrix metalloproteinase-9, and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J Neuroimmunol 1999; 99: 19-26
141. Liuzzi GM, Trojano M, Fanelli M, et al. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 2002; 8: 222-228
142. Waubant E, Goodkin D, Bostrom A, et al. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 2003; 60: 52-57
143. Waubant E, Goodkin DE, Gee L, et al. Serum MMP-9, and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999; 53: 1397-1401
144. Alvarez JI, and Teale JM. Multiple expression of matrix metalloproteinases in murine neurocysticercosis: implications for leukocyte migration through multiple central nervous system barriers. Brain Res 2008; 1214: 145-158
145. Graesser D, Mahooti S, and Madri JA. Distinct roles for matrix metalloproteinase-2, and alpha4 integrin in autoimmune T cell extravasation, and residency in brain parenchyma during experimental autoimmune encephalomyelitis. J Neuroimmunol 2000; 109: 121-131
146. Liu W, Hendren J, Qin XJ, et al. Normobaric hyperoxia attenuates early blood-brain barrier disruption by inhibiting MMP-9-mediated occludin degradation in focal cerebral ischemia. J Neurochem 2009; 108: 811-820
147. Reijerkerk A, Kooij G, van Der Pol SM, et al. Diapedesis of monocytes is associated with MMPmediated occludin disappearance in brain endothelial cells. FASEB J 2006; 20: 2550-2552
148. Rosenberg GA, and Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus 2007; 22: E4
149. Zozulya AL, Reinke E, Baiu DC, et al. Dendritic cell transmigration through brain microvessel endothelium is regulated by MIP-1alpha chemokine, and matrix metalloproteinases. J Immunol 2007; 178: 520-529
150. Maeda A, and Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55: 300-309
151. van Horssen J, Vos CM, Admiraal L, et al. Matrix metalloproteinase-19 is highly expressed in active multiple sclerosis lesions. Neuropathol Appl Neurobiol 2006; 32: 585-593
152. Hansmann F, Herder V, Kalkuhl A, et al. Matrix metalloproteinase-12 deficiency ameliorates the clinical course, and demyelination in Theiler?s murine encephalomyelitis. Acta Neuropathol 2012; 124: 127-142
153. Goncalves DaSilva A, Liaw L, and Yong VW. Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyelitis disease in C57BL/6 Mice. Am J Pathol 2010; 177: 1448-1458
154. Keedy A. An overview of intracranial aneurysms. McGill J Med 2006; 9: 141-146
155. Novitzke J. The basics of brain aneurysms: a guide for patients. J Vasc Intervent Neurol 2008; 1: 89-90
156. Kaku Y, Watarai H, Kokuzawa J, et al. Treatment of cerebral aneurysms: surgical clipping, and coil embolization. Intervent Neuroradiol 2007; 13: 68-72
157. Bruno G, Todor R, Lewis I, et al. Vascular extracellular matrix remodeling in cerebral aneurysms. J Neurosurg 1998; 89: 431-440
158. Chyatte D, and Lewis I. Gelatinase activity, and the occurrence of cerebral aneurysms. Stroke 1997; 28: 799-804
159. Kim SC, Singh M, Huang J, et al. Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery 1997; 41: 642-666. discussion 6-7
160. Perrotta I, Sciangula A, Aquila S, et al. Matrix metalloproteinase-9 expression in calcified human aortic valves: a histopathologic, immunohistochemical, and ultrastructural study. Appl Immunohistochem Mol Morphol 2016; 24: 128-137
161. Zhao Y-G, Meng F-X, Li B-W, et al. Gelatinases promote calcification of vascular smooth muscle cells by up-regulating bone morphogenetic protein-2. Biochem Biophys Res Commun 2016; 470: 287-293
162. Bhatia S, Sekula RF, Quigley MR, et al. Role of calcification in the outcomes of treated, unruptured, intracerebral aneurysms. Acta Neurochirurg 2011; 153: 905-911
163. Thompson RW, and Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann N Y Acad Sci 1999; 878: 159-178
164. Tsuji K, Aoki T, Fukuda M, et al. Statins as a candidate of drugs for intracranial aneurysm treatment. Health 2014; 6: 1459-1466
165. Nuki Y, Tsou TL, Kurihara C, et al. Elastase-induced intracranial aneurysms in hypertensive mice. Hypertension 2009; 54: 1337-1344
166. Xiong W, Knispel RA, Dietz HC, et al. Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. J Vasc Surg 2008; 47: 166-172; discussion 72
167. Aoki T, Kataoka H, Ishibashi R, et al. Pitavastatin suppresses formation, and progression of cerebral aneurysms through inhibition of the nuclear factor kappaB pathway. Neurosurgery 2009; 64: 357-365. discussion 65-66
168. Aoki T, Kataoka H, Ishibashi R, et al. Simvastatin suppresses the progression of experimentally induced cerebral aneurysms in rats. Stroke 2008; 39: 1276-1285
169. Yoshimura Y, Murakami Y, Saitoh M, et al. Statin use, and risk of cerebral aneurysm rupture: a hospital-based case-control study in Japan. J Stroke Cerebrovasc Dis 2014; 23: 343-348
170. WHO. The top 10 causes of death -fact sheet N-310, 2014
171. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global, and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383: 245-254
172. Zlokovic BV. Remodeling after stroke. Nat Med 2006; 12: 390-391
173. Clark AW, Krekoski CA, Bou SS, et al. Increased gelatinase A (MMP-2), and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 1997; 238: 53-56
174. Sole S, Petegnief V, Gorina R, et al. Activation of matrix metalloproteinase-3, and agrin cleavage in cerebral ischemia/reperfusion. J Neuropathol Exp Neurol 2004; 63: 338-349
175. Lo EH, Wang X, and Cuzner ML. Extracellular proteolysis in brain injury, and inflammation: role for plasminogen activators, and matrix metalloproteinases. J Neurosci Res 2002; 69: 1-9
176. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic, and hemorrhagic human stroke. Stroke 2006; 37: 1399-1406
177. Rosenberg GA, Navratil M, Barone F, et al. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 1996; 16: 360-366
178. Hamann GF, Liebetrau M, Martens H, et al. Microvascular basal lamina injury after experimental focal cerebral ischemia, and reperfusion in the rat. J Cereb Blood Flow Metab 2002; 22: 526-533
179. Kelly MA, Shuaib A, and Todd KG. Matrix metalloproteinase activation, and blood-brain barrier breakdown following thrombolysis. Exp Neurol 2006; 200: 38-49
180. Sumii T, and Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002; 33: 831-836
181. Gasche Y, Fujimura M, Morita-Fujimura Y, et al. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 1999; 19: 1020-1028
182. Planas AM, Sole S, and Justicia C. Expression, and activation of matrix metalloproteinase-2, and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 2001; 8: 834-846
183. Gidday JM, Gasche YG, Copin J-C, et al. Leukocytederived matrix metalloproteinase-9 mediates blood-brain barrier breakdown, and is proinflammatory after transient focal cerebral ischemia, 2005; 289(2): H558-H568
184. Ludewig P, Sedlacik J, Gelderblom M, et al. Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits MMP-9-mediated blood-brain-barrier breakdown in a mouse model for ischemic stroke. Circ Res 2013; 113: 1013-1022
185. Suzuki Y, Nagai N, Umemura K, et al. Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost 2007; 5: 1732-1739
186. Suzuki Y, Nagai N, Yamakawa K, et al. Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein. Blood 2009; 114: 3352-3358
187. Rosell A, and Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008; 8: 82-89
188. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-744
189. Hsu JY, McKeon R, Goussev S, et al. Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J Neurosci 2006; 26: 9841-9850
190. Nagy V, Bozdagi O, Matynia A, et al. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation, and memory. J Neurosci 2006; 26: 1923-1934
191. Zhao BQ, Wang S, Kim HY, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006; 12: 441-445
192. Ngugi AK, Bottomley C, Kleinschmidt I, et al. Estimation of the burden of active, and life-time epilepsy: a meta-analytic approach. Epilepsia 2010; 51: 883-890
193. WHO. Epilepsy Fact sheet N-999, http://www.who.int/mediacentre/factsheets/fs999/en/2012
194. Shafer PO. About epilepsy: The basics. Landover, MD: Epilepsy Foundation, 2014
195. Bazil C, MorrellMand Pedley T. Epilepsy. In: Rowland L (ed.) Merritt?s neurology, 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005, pp.990-1008
196. Mizoguchi H, Nakade J, Tachibana M, et al. Matrix metalloproteinase-9 contributes to kindled seizure development in pentylenetetrazole-treated mice by converting pro-BDNF to mature BDNF in the hippocampus. J Neurosci 2011; 31: 12963-12971
197. Wilczynski GM, Konopacki FA, Wilczek E, et al. Important role of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol 2008; 180: 1021-1035
198. Quirico-Santos T, Nascimento Mello A, Casimiro Gomes A, et al. Increased metalloprotease activity in the epileptogenic lesion -lobectomy reduces metalloprotease activity, and urokinase-type uPAR circulating levels. Brain Res 2013; 1538: 172-181
199. Szklarczyk A, Lapinska J, Rylski M, et al. Matrix metalloproteinase-9 undergoes expression, and activation during dendritic remodeling in adult hippocampus. J Neurosci 2002; 22: 920-930
200. Takacs E, Nyilas R, Szepesi Z, et al. Matrix metalloproteinase-9 activity increased by two different types of epileptic seizures that do not induce neuronal death: a possible role in homeostatic synaptic plasticity. Neurochem Int 2010; 56: 799-809
201. Li YJ, Wang ZH, Zhang B, et al. Disruption of the blood-brain barrier after generalized tonic-clonic seizures correlates with cerebrospinal fluid MMP-9 levels. J Neuroinflammation 2013; 10: 80
202. Suenaga N, Ichiyama T, Kubota M, et al. Roles of matrix metalloproteinase-9, and tissue inhibitors of metalloproteinases 1 in acute encephalopathy following prolonged febrile seizures. J Neurol Sci 2008; 266: 126-130
203. Konopka A, Grajkowska W, Ziemianska K, et al. Matrix metalloproteinase-9 (MMP-9) in human intractable epilepsy caused by focal cortical dysplasia. Epilepsy Res 2013; 104: 45-58
204. Zhang JW, Deb S, and Gottschall PE. Regional, and agerelated expression of gelatinases in the brains of young, and old rats after treatment with kainic acid. Neurosci Lett 2000; 295: 9-12
205. Alonso-Nanclares L, and DeFelipe J. Alterations of the microvascular network in the sclerotic hippocampus of patients with temporal lobe epilepsy. Epilepsy Behav 2014; 38: 48-52
206. Kastanauskaite A, Alonso-Nanclares L, Blazquez-Llorca L, et al. Alterations of the microvascular network in sclerotic hippocampi from patients with epilepsy. J Neuropathol Exp Neurol 2009; 68: 939-950
207. Marchi N, Oby E, Batra A, et al. In vivo, and in vitro effects of pilocarpine: relevance to ictogenesis. Epilepsia 2007; 48: 1934-1946
208. Rigau V, Morin M, Rousset MC, et al. Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain 2007; 130: 1942-1956
209. Tomkins O, Shelef I, Kaizerman I, et al. Blood-brain barrier disruption in post-traumatic epilepsy. J Neurol Neurosurg Psychiatry 2008; 79: 774-777
210. van Vliet EA, da Costa Araújo S, Redeker S, et al. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007; 130: 521-534
211. Marchi N, Angelov L, Masaryk T, et al. Seizurepromoting effect of blood-brain barrier disruption. Epilepsia 2007; 48: 732-742
212. Marchi N, Teng Q, Ghosh C, et al. Blood-brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity. Brain Res 2010; 1353: 176-186
213. Harkness KA, Adamson P, Sussman JD, et al. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 2000; 123(Pt 4): 698-709
214. WHO, and International AsD. Dementia: a public health priority, http://www.who.int/mental-health/publications/dementia-report-2012/en/2012 (2012, accessed 3 June 2016
215. Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review, and metaanalysis. Alzheimers Dement 2013; 9: 63e2-75e2
216. Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting the global burden of Alzheimer?s disease. Alzheimer Dement 2007; 3: 186-191
217. Eikelenboom P, Bate C, Van Gool WA, et al. Neuroinflammation in Alzheimer?s disease, and prion disease. Glia 2002; 40: 232-239
218. Tiraboschi P, Hansen LA, Thal LJ, et al. The importance of neuritic plaques, and tangles to the development, and evolution of AD. Neurology 2004; 62: 1984-1989
219. Yan P, Hu X, Song H, et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro, and compact plaques in situ. J Biol Chem 2006; 281: 24566-24574
220. Py NA, Bonnet AE, Bernard A, et al. Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of Alzheimer?s disease: evidence for a pro-amyloidogenic role of MT1-MMP. Front Aging Neurosci 2014; 6: 247
221. Asahina M, Yoshiyama Y, and Hattori T. Expression of matrix metalloproteinase-9, and urinary-type plasminogen activator in Alzheimer?s disease brain. Clin Neuropathol 2001; 20: 60-63
222. Backstrom JR, Lim GP, Cullen MJ, et al. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus, and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 1996; 16: 7910-7919
223. Bruno MA, Mufson EJ, Wuu J, et al. Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J Neuropathol Exp Neurol 2009; 68: 1309-1318
224. Yoshiyama Y, Asahina M, and Hattori T. Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer?s disease brain. Acta Neuropathol 2000; 99: 91-95
225. Horstmann S, Budig L, Gardner H, et al. Matrix metalloproteinases in peripheral blood, and cerebrospinal fluid in patients with Alzheimer?s disease. Int Psychogeriatr 2010; 22: 966-972
226. Lorenzl S, Albers DS, Relkin N, et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer?s disease. Neurochem Int 2003; 43: 191-196
227. Deb S, and Gottschall PE. Increased production of matrix metalloproteinases in enriched astrocyte, and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem 1996; 66: 1641-1647
228. Hartz AM, Bauer B, Soldner EL, et al. Amyloid-beta contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice, and in humans with cerebral amyloid angiopathy. Stroke 2012; 43: 514-523
229. Yin KJ, Cirrito JR, Yan P, et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci 2006; 26: 10939-10948
230. Molecular cell biology of the endothelium in development, and diseases. In: Abstracts of the 4th symposium on the biology of endothelial cells, Munich, 18-20 July 2003 (Angiogenesis 2002; 5: 281-354
231. Caragounis A, Du T, Filiz G, et al. Differential modulation of Alzheimer?s disease amyloid beta-peptide accumulation by diverse classes of metal ligands. Biochem J 2007; 407: 435-450
232. White AR, Du T, Laughton KM, et al. Degradation of the Alzheimer disease amyloid beta-peptide by metaldependent up-regulation of metalloprotease activity. J Biol Chem 2006; 281: 17670-17680
233. Ridnour LA, Dhanapal S, Hoos M, et al. Nitric oxidemediated regulation of beta-amyloid clearance via alterations of MMP-9/TIMP-1. J Neurochem 2012; 123: 736-749
234. Wang Y, and Lee J. Mmp-9 attenuates amyloid plaque pathogenesis in APP/PS1 Mice. Am J Pathol 2011; 6(4): S261
235. Liao MC, and Van Nostrand WE. Degradation of soluble, and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro. Biochemistry 2010; 49: 1127-1136
236. European Parkinson?s Disease Association (EPDA). Life with Parkinson?s Part 1. Brussels: EPDA, 2014
237. Parkinson J. An essay on the shaking palsy. London: Printed by Whittingham, and Rowland for Sherwood, Neely, and Jones, 1817
238. Chung YC, Kim YS, Bok E, et al. MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson?s disease. Mediators Inflamm 2013; 2013: 370526
239. Van Der Perren A, Macchi F, Toelen J, et al. FK506 reduces neuroinflammation, and dopaminergic neurodegeneration in an alpha-synuclein-based rat model for Parkinson?s disease. Neurobiol Aging 2015; 36: 1559-1568
240. Lorenzl S, Albers DS, Narr S, et al. Expression of MMP-2, MMP-9, and MMP-1, and their endogenous counterregulators TIMP-1, and TIMP-2 in postmortem brain tissue of Parkinson?s disease. Exp Neurol 2002; 178: 13-20
241. Choi DH, Kim EM, Son HJ, et al. A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J Neurochem 2008; 106: 405-415
242. Cho Y, Son HJ, Kim EM, et al. Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3. Neurotox Res 2009; 16: 361-371
243. Kim ST, Kim EM, Choi JH, et al. Matrix metalloproteinase-3 contributes to vulnerability of the nigral dopaminergic neurons. Neurochem Int 2010; 56: 161-167
244. Shin EJ, Kim EM, Lee JA, et al. Matrix metalloproteinase-3 is activated by HtrA2/Omi in dopaminergic cells: relevance to Parkinson?s disease. Neurochem Int 2012; 60: 249-256
245. Sung JY, Park SM, Lee CH, et al. Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J Biol Chem 2005; 280: 25216-25224
246. Kim S, Cho SH, Kim KY, et al. Alpha-synuclein induces migration of BV-2 microglial cells by up-regulation of CD44, and MT1-MMP. J Neurochem 2009; 109: 1483-1496
247. Monahan AJ, Warren M, and Carvey PM. Neuroinflammation, and peripheral immune infiltration in Parkinson?s disease: an autoimmune hypothesis. Cell Transplant 2008; 17: 363-372
248. Reale M, Iarlori C, Thomas A, et al. Peripheral cytokines profile in Parkinson?s disease. Brain Behav Immun 2009; 23: 55-63
249. Rite I, Machado A, Cano J, et al. Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem 2007; 101: 1567-1582
250. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence, and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013. Available from: http://globocan.iarc.fr (accessed 17 March 2016
251. World Health Organization (WHO). World cancer report 2014. Geneva: WHO, 2014
252. Holland EC. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci USA 2000; 97: 6242-6244
253. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain 2007; 130: 2596-2606
254. Ohgaki H, and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic, and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-489
255. Ii M, Yamamoto H, Adachi Y, et al. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 2006; 231: 20-27
256. Shiomi T, and Okada Y. MT1-MMP, and MMP-7 in invasion, and metastasis of human cancers. Cancer Metastasis Rev 2003; 22: 145-152
257. Juncker-Jensen A, Deryugina EI, Rimann I, et al. Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation, and metastatic dissemination. Cancer Res 2013; 73: 4196-4211
258. Hummel V, Kallmann BA, Wagner S, et al. Production of MMPs in human cerebral endothelial cells, and their role in shedding adhesion molecules. J Neuropathol Exp Neurol 2001; 60: 320-327
259. Nakamura H, Suenaga N, Taniwaki K, et al. Constitutive, and induced CD44 shedding by ADAMlike proteases, and membrane-type 1 matrix metalloproteinase. Cancer Res 2004; 64: 876-882
260. Hanley WD, Napier SL, Burdick MM, et al. Variant isoforms of CD44 are P-and L-selectin ligands on colon carcinoma cells. FASEB J 2006; 20: 337-339
261. Napier SL, Healy ZR, Schnaar RL, et al. Selectin ligand expression regulates the initial vascular interactions of colon carcinoma cells -the roles of CD44V, and alternative sialofucosylated selectin ligands. J Biol Chem 2007; 282: 3433-3441
262. Thomas SN, Zhu F, Schnaar RL, et al. Carcinoembryonic antigen, and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E-and L-selectin in shear flow. J Biol Chem 2008; 283: 15647-15655
263. Fazakas C, Wilhelm I, Nagyoszi P, et al. Transmigration of melanoma cells through the bloodbrain barrier: role of endothelial tight junctions, and melanoma-released serine proteases. PLoS ONE 2011; 6: e20758
264. Lee KY, Kim YJ, Yoo H, et al. Human brain endothelial cell-derived COX-2 facilitates extravasation of breast cancer cells across the blood-brain barrier. Anticancer Res 2011; 31: 4307-4313
265. Lorger M, and Felding-Habermann B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol 2010; 176: 2958-2971
266. Eibl RH, Pietsch T, Moll J, et al. Expression of variant CD44 epitopes in human astrocytic brain tumors. J Neurooncol 1995; 26: 165-170
267. Naor D, Nedvetzki S, Golan I, et al. CD44 in cancer. Crit Rev Cl Lab Sci 2002; 39: 527-579
268. Suenaga N, Mori H, Itoh Y, et al. CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. Oncogene 2005; 24: 859-868
269. Lesley J, Hyman R, and Kincade PW. CD44, and its interaction with extracellular matrix. Adv Immunol 1993; 54: 271-335
270. Jalkanen S, and Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol 1992; 116: 817-825
271. Wang M, Wang T, Liu S, et al. The expression of matrix metalloproteinase-2, and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 2003 (Biochim Biophys Acta 20: 65-72
272. Annabi B, Bouzeghrane M, Currie JC, et al. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion, and triggers CD44 cell surface shedding: implication in tumor metastasis. Clin Exp Metastasis 2005; 22: 429-439
273. Bauvois B. New facets of matrix metalloproteinases MMP-2, and MMP-9 as cell surface transducers: outside-in signaling, and relationship to tumor progression. Biochim Biophys Acta 2012; 1825: 29-36
274. Nakada M, Nakamura H, Ikeda E, et al. Expression, and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 1999; 154: 417-428
275. Matsumoto S, Katoh M, Saito S, et al. Identification of soluble type of membrane-type matrix metalloproteinase-3 formed by alternatively spliced mRNA. Biochim Biophys Acta 1997; 1354: 159-170
276. Shimada T, Nakamura H, Ohuchi E, et al. Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase. Eur J Biochem 1999; 262: 907-914
277. Belien AT, Paganetti PA, and Schwab ME. Membranetype 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol 1999; 144: 373-384
278. Xu D, Sun Y, Bao G, et al. MMP-1 overexpression induced by IL-1beta: possible mechanism for inflammation in degenerative lumbar facet joint. J Orthop Sci 2013; 18: 1012-1019
279. Pei D. Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage. Cell Res 1999; 9: 291-303
280. Velasco G, Cal S, Merlos-Suarez A, et al. Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res 2000; 60: 877-882
281. Sounni NE, Devy L, Hajitou A, et al. MT1-MMP expression promotes tumor growth, and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 2002; 16: 555-564
282. Birbrair A, Zhang T, Wang ZM, et al. Type-1 pericytes participate in fibrous tissue deposition in aged skeletal muscle. Am J Physiol Cell Physiol 2013; 305: C1098-C1113
283. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Investigat 1999; 103: 1237-1241
284. Bronger H, Konig J, Kopplow K, et al. ABCC drug efflux pumps, and organic anion uptake transporters in human gliomas, and the blood-tumor barrier. Cancer Res 2005; 65: 11419-11428
285. Groothuis DR. The blood-brain, and blood-tumor barriers: a review of strategies for increasing drug delivery. NeuroOncology 2000; 2: 45-59
286. Noell S, Wolburg-Buchholz K, Mack AF, et al. Dynamics of expression patterns of AQP4, dystroglycan, agrin, and matrix metalloproteinases in human glioblastoma. Cell Tissue Res 2012; 347: 429-441
287. Mariani CL, Boozer LB, Braxton AM, et al. Evaluation of matrix metalloproteinase-2, and -9 in the cerebrospinal fluid of dogs with intracranial tumors. Am J Vet Res 2013; 74: 122-129
288. Turba ME, Forni M, Gandini G, et al. Recruited leukocytes, and local synthesis account for increased matrix metalloproteinase-9 activity in cerebrospinal fluid of dogs with central nervous system neoplasm. J Neurooncol 2007; 81: 123-129
289. Ashley RA. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD Clinical Research Team. Ann N Y Acad Sci 1999; 878: 335-346
290. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mechanisms. Adv Dent Res 1998; 12: 12-26
291. Preshaw PM, Hefti AF, Novak MJ, et al. Subantimicrobial dose doxycycline enhances the efficacy of scaling, and root planing in chronic periodontitis: a multicenter trial. J Periodontol 2004; 75: 1068-1076
292. Brundula V, Rewcastle NB, Metz LM, et al. Targeting leukocyte MMPs, and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125: 1297-1308
293. Gijbels K, Galardy RE, and Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994; 94: 2177-2182
294. Graesser D, Mahooti S, Haas T, et al. The interrelationship of alpha4 integrin, and matrix metalloproteinase-2 in the pathogenesis of experimental autoimmune encephalomyelitis. Lab Invest 1998; 78: 1445-1458
295. Hewson AK, Smith T, Leonard JP, et al. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 1995; 44: 345-349
296. Eccles SA, Box GM, Court WJ, et al. Control of lymphatic, and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996; 56: 2815-2822
297. Sledge GW Jr, Qulali M, Goulet R, et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth, and metastasis in athymic mice. J Natl Cancer Inst 1995; 87: 1546-1550
298. Watson SA, Morris TM, Parsons SL, et al. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br J Cancer 1996; 74: 1354-1358
299. Watson SA, Morris TM, Robinson G, et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55: 3629-3633
300. Asahi M, Asahi K, Jung JC, et al. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout, and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000; 20: 1681-1689
301. Pfefferkorn T, and Rosenberg GA. Closure of the bloodbrain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 2003; 34: 2025-2030
302. Sood RR, Taheri S, Candelario-Jalil E, et al. Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired longterm recovery after stroke in rat brain. J Cereb Blood Flow Metab 2008; 28: 431-438
303. Minagar A, Alexander JS, Schwendimann RN, et al. Combination therapy with interferon beta-1a, and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol 2008; 65: 199-204
304. Fagan SC, Waller JL, Nichols FT, et al. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke 2010; 41: 2283-2287
305. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007; 69: 1404-1410
306. Groves M, Puduvalli V, Conrad C, et al. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity, and anticonvulsant status. J Neurooncol 2006; 80: 83-90
307. Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent, and progressive glioblastoma multiforme. J Clin Oncol 2002; 20: 1383-1388
308. New P, Mikkelsen T, Phuphanich S, et al. A phase I/II study of COL-3 administered on a continuous oral schedule in patients with recurrent high grade glioma. Preliminary results of the NABTT 9809 clinical trial. Neuro-Oncology. 2002; 4: 373
309. Rudek MA, New P, Mikkelsen T, et al. Phase I, and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. J Neurooncol 2011; 105: 375-381
310. Coussens LM, and Werb Z. Inflammation, and cancer. Nature 2002; 420: 860-867
311. Dezube BJ, Krown SE, Lee JY, et al. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi?s sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 2006; 24: 1389-1394
312. Drummond AH, Beckett P, Brown PD, et al. Preclinical, and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 1999; 878: 228-235
313. Goffin JR, Anderson IC, Supko JG, et al. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin, and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 2005; 11: 3417-3424
314. Macaulay VM, O?Byrne KJ, Saunders MP, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999; 5: 513-520
315. Miller KD, Saphner TJ, Waterhouse DM, et al. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 2004; 10: 1971-1975
316. Rudek MA, Figg WD, Dyer V, et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001; 19: 584-592
317. Skiles JW, Gonnella NC, and Jeng AY. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr Med Chem 2004; 11: 2911-2977
318. Sparano JA, Bernardo P, Stephenson P, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004; 22: 4683-4690
319. Vandenbroucke RE, and Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov 2014; 13: 904-927
320. Zabad RK, Metz LM, Todoruk TR, et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 2007; 13: 517-526
321. Zhang Y, Metz LM, Yong VW, et al. Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci 2008; 35: 185-191
322. Chu QC, Forouzesh B, Syed S, et al. A phase II, and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs 2007; 25: 359-367